AU2011224238B2 - Parenteral formulations of macrolide antibiotics - Google Patents

Parenteral formulations of macrolide antibiotics Download PDF

Info

Publication number
AU2011224238B2
AU2011224238B2 AU2011224238A AU2011224238A AU2011224238B2 AU 2011224238 B2 AU2011224238 B2 AU 2011224238B2 AU 2011224238 A AU2011224238 A AU 2011224238A AU 2011224238 A AU2011224238 A AU 2011224238A AU 2011224238 B2 AU2011224238 B2 AU 2011224238B2
Authority
AU
Australia
Prior art keywords
composition
cem
another embodiment
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011224238A
Other languages
English (en)
Other versions
AU2011224238A1 (en
Inventor
Prabhavathi Fernandes
David E. Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cempra Pharmaceuticals Inc
Original Assignee
Cempra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cempra Pharmaceuticals Inc filed Critical Cempra Pharmaceuticals Inc
Publication of AU2011224238A1 publication Critical patent/AU2011224238A1/en
Application granted granted Critical
Publication of AU2011224238B2 publication Critical patent/AU2011224238B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2011224238A 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics Ceased AU2011224238B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31241710P 2010-03-10 2010-03-10
US61/312,417 2010-03-10
PCT/US2011/027984 WO2011112864A1 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Publications (2)

Publication Number Publication Date
AU2011224238A1 AU2011224238A1 (en) 2012-10-04
AU2011224238B2 true AU2011224238B2 (en) 2015-11-26

Family

ID=44563855

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011224238A Ceased AU2011224238B2 (en) 2010-03-10 2011-03-10 Parenteral formulations of macrolide antibiotics

Country Status (11)

Country Link
US (3) US20130045937A1 (https=)
EP (1) EP2544537B1 (https=)
JP (1) JP5890785B2 (https=)
CN (2) CN109091489A (https=)
AU (1) AU2011224238B2 (https=)
CA (1) CA2792616A1 (https=)
DK (1) DK2544537T3 (https=)
ES (1) ES2637072T3 (https=)
PL (1) PL2544537T3 (https=)
SI (1) SI2544537T1 (https=)
WO (1) WO2011112864A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638549A4 (en) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc NEW ANTIBACTERIAL AGENTS
EP2214484A4 (en) 2007-10-25 2013-01-02 Cempra Pharmaceuticals Inc PROCESS FOR PREPARING ANTIBACTERIAL MAKROLIDE AGENTS
JP5711135B2 (ja) 2008-10-24 2015-04-30 センプラ ファーマシューティカルズ，インコーポレイテッド 胃腸疾患を治療するための方法
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
ES2608285T3 (es) 2009-09-10 2017-04-07 Cempra Pharmaceuticals, Inc. Procedimientos para el tratamiento de paludismo, tuberculosis y enfermedades por MAC
MX361413B (es) 2010-03-22 2018-12-05 Cempra Pharmaceuticals Inc Star Formas cristalinas de un macrólido y usos para las mismas.
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
EP2613630A4 (en) 2010-09-10 2014-01-15 Cempra Pharmaceuticals Inc HYDROGEN BOND FOR THE PREPARATION OF FLUOROCHETOLIDES FOR THE TREATMENT OF DISEASES
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
NZ700182A (en) * 2012-03-27 2017-02-24 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
AU2014239959A1 (en) * 2013-03-14 2015-10-01 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
CN105188712A (zh) 2013-03-15 2015-12-23 森普拉制药公司 用于制备大环内酯抗菌剂的收敛方法
JP6437523B2 (ja) 2013-04-04 2018-12-12 プレジデント アンド フェローズ オブ ハーバード カレッジ マクロライドならびにそれらの調製および使用の方法
EP3895724B1 (en) 2013-05-22 2025-06-25 Zensun (Shanghai) Science and Technology, Co., Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
SG11201700827RA (en) * 2014-08-05 2017-03-30 Cempra Pharmaceuticals Inc Powder oral suspension formulations of antibacterial agents
CN106998685A (zh) 2014-10-08 2017-08-01 哈佛大学的校长及成员们 14‑元酮内酯及其制备和使用方法
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EP3273969A4 (en) 2015-03-25 2018-11-21 President and Fellows of Harvard College Macrolides with modified desosamine sugars and uses thereof
BR112021026480A2 (pt) * 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents
US20080221048A1 (en) * 2004-03-17 2008-09-11 App Pharmaceuticals, Llc. Lyophilized azithromycin formulation
US20090156517A1 (en) * 2006-08-25 2009-06-18 Hesheng Zhang Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CN101045063B (zh) * 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100164A1 (en) * 2003-03-10 2006-05-11 Chang-Hsing Liang Novel antibacterial agents
US20080221048A1 (en) * 2004-03-17 2008-09-11 App Pharmaceuticals, Llc. Lyophilized azithromycin formulation
US20090156517A1 (en) * 2006-08-25 2009-06-18 Hesheng Zhang Stable pharmaceutical compositions of aminoglycoside antibiotics, ion-chelating agents, and buffers

Also Published As

Publication number Publication date
CN109091489A (zh) 2018-12-28
JP2013522229A (ja) 2013-06-13
PL2544537T3 (pl) 2017-10-31
AU2011224238A1 (en) 2012-10-04
SI2544537T1 (sl) 2017-12-29
US20190054059A1 (en) 2019-02-21
US20200276150A1 (en) 2020-09-03
EP2544537B1 (en) 2017-05-10
WO2011112864A1 (en) 2011-09-15
EP2544537A4 (en) 2014-05-14
CN102811616A (zh) 2012-12-05
US20130045937A1 (en) 2013-02-21
EP2544537A1 (en) 2013-01-16
JP5890785B2 (ja) 2016-03-22
ES2637072T3 (es) 2017-10-10
CA2792616A1 (en) 2011-09-15
DK2544537T3 (en) 2017-08-28

Similar Documents

Publication Publication Date Title
AU2011224238B2 (en) Parenteral formulations of macrolide antibiotics
JP6378408B2 (ja) マクロライド抗生物質を投与するための非経口製剤
CN101045063B (zh) 注射用克拉霉素水溶性制剂
HK1180184A (en) Parenteral formulations of macrolide antibiotics
HK1180184B (en) Parenteral formulations of macrolide antibiotics
HK40002820A (en) Parenteral formulations of macrolide antibiotics
HK1179115A (en) Parenteral formulations of macrolide antibiotics
AU2018220172A1 (en) Triazole-containing macrolides and ophthalmic uses therefor
HK1208622B (zh) 用於施用大环内酯抗生素的肠胃外制剂
AU2018230347A1 (en) Compositions and methods for treating dry eye diseases

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ PEREIRA, DAVID E. AND FERNANDES, PRABHAVATHI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired